Denna sida på svenska
Loading profile information...

Publications

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker Pm, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al
The New England journal of medicine 2017;376(16):1527-1539

Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart Transplantation
Zabarovskaja S, Hage C, Gabrielsen A, Mellbin L, Lund Lh
Heart, lung & circulation 2017;26(2):143-149

Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort
Smaradottir Mi, Ritsinger V, Gyberg V, Norhammar A, Näsman P, Mellbin Lg
Diabetes & vascular disease research 2017;14(2):69-76

Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor
Norhammar A, Mellbin L, Cosentino F
European journal of preventive cardiology 2017;24(3_suppl):52-60

Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort
Ritsinger V, Brismar K, Malmberg K, Mellbin L, Näsman P, Rydén L, et al
Diabetes & vascular disease research 2017;14(2):77-87

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Ridker Pm, Tardif Jc, Amarenco P, Duggan W, Glynn Rj, Jukema Jw, et al
The New England journal of medicine 2017;376(16):1517-1526

New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations: Reduction of Acute Coronary Events With Pioglitazone
Rydén L, Mellbin L
Circulation 2017;135(20):1894-1896

Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome
Morici N, Savonitto S, Ponticelli C, Schrieks Ic, Nozza A, Cosentino F, et al
The American journal of medicine 2017;130(9):1068-1075

The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial
Rautio A, Boman K, Gerstein Hc, Hernestål-boman J, Lee Sf, Olofsson M, et al
Diabetes & vascular disease research 2017;14(4):345-352

The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial
Van Steen Sc, Schrieks Ic, Hoekstra Jb, Lincoff Am, Tardif Jc, Mellbin Lg, et al
European journal of preventive cardiology 2017;24(8):858-866

The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV: A Survey From the European Society of Cardiology
Shahim B, De Bacquer D, De Backer G, Gyberg V, Kotseva K, Mellbin L, et al
Diabetes care 2017;40(9):1233-1240

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
Rydén L, Shahim B, Mellbin L
Clinical therapeutics 2016;38(6):1279-1287

Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study
Arnetz L, Hage C, Brismar K, Catrina Sb, Norhammar A, Lundman P, et al
Diabetes & vascular disease research 2016;13(4):307-11

Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes
Zabarovskaja S, Hage C, Linde C, Daubert Jc, Donal E, Gabrielsen A, et al
International journal of cardiology 2015;189():6-11

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
Hage C, Lund Lh, Donal E, Daubert Jc, Linde C, Mellbin L
Open heart 2015;2(1):e000260-

Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study
Gyberg V, Kotseva K, Dallongeville J, Backer Gd, Mellbin L, Rydén L, et al
European journal of preventive cardiology 2015;22(6):753-61

Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity
Arnetz L, Hage C, Ekberg Nr, Alvarsson M, Brismar K, Norhammar A, et al
GROWTH HORMONE & IGF RESEARCH 2015;25(6):298-303

Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology
Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al
Cardiovascular diabetology 2015;14():133-

Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial
Origin Trial Investigators
Diabetes care 2015;38(1):22-8

Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls
Mohammad Aa, Rahbar A, Lui Wo, Davoudi B, Catrina A, Stragliotto G, et al
PloS one 2014;9(12):e113740-

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial
Lincoff Am, Tardif Jc, Schwartz Gg, Nicholls Sj, Rydén L, Neal B, et al
JAMA 2014;311(15):1515-25

ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary
Dev Collaboration European Assoc, Esc, Task Force Diabet Prediabet, Ryden L, Grant Pj, Anker Sd, et al
DIABETES & VASCULAR DISEASE RESEARCH 2014;11(3):133-73

The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management
Katz P, Leiter La, Mellbin L, Rydén L
Diabetes & vascular disease research 2014;11(6):395-409

The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study
Hage C, Brismar K, Lundman P, Norhammar A, Ryden L, Mellbin L
DIABETES & VASCULAR DISEASE RESEARCH 2014;11(4):290-293

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
Origin Trial Investigators, Mellbin Lg, Ryden L, Riddle Mc, Probstfield J, Rosenstock J, et al
EUROPEAN HEART JOURNAL 2013;34(40):3137-44

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Easd, Esc, Ryden L, Grant Pj, Anker Sd, Berne C, et al
EUROPEAN HEART JOURNAL 2013;34(39):3035-87

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Europejskim Towarzystwem Badan Nad, Ryden L, Grant Pj, Anker Sd, Berne C, Cosentino F, et al
KARDIOLOGIA POLSKA 2013;:S319-94

Fasting glucose, HbA1c, or oral glucose tolerance testing for the detection of glucose abnormalities in patients with acute coronary syndromes
Hage C, Lundman P, Rydén L, Mellbin L
European journal of preventive cardiology 2013;20(4):549-54

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study
Hage C, Brismar K, Efendic S, Lundman P, Rydén L, Mellbin L
Journal of internal medicine 2013;273(4):410-21

The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial
Mellbin Lg, Malmberg K, Rydén L, Wedel H, Vestberg D, Lind M
European heart journal 2013;34(5):374-9

Triglycerides-diabetes association in healthy middle-aged men: Modified by physical fitness? A long term follow-up of 1962 Norwegian men in the Oslo Ischemia Study
Skretteberg Pt, Grytten An, Gjertsen K, Grundvold I, Kjeldsen Se, Erikssen J, et al
DIABETES RESEARCH AND CLINICAL PRACTICE 2013;101(2):201-9

Basal insulin and cardiovascular and other outcomes in dysglycemia
Origin Trial Investigators, Gerstein Hc, Bosch J, Dagenais Gr, Díaz R, Jung H, et al
The New England journal of medicine 2012;367(4):319-28

Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction A report from the DIGAMI 2 trial
Mellbin Lg, Bjerre M, Thiel S, Hansen Tk
DIABETES CARE 2012;35(4):911-7

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial
Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, et al
Diabetologia 2012;55(1):36-45

Evidence for a beneficial effect of glucose-insulin-potassium in patients with acute coronary syndromes: Did the IMMEDIATE trial solve an unanswered question?
Mellbin L, Rydén L
Expert review of cardiovascular therapy 2012;10(9):1097-9

Glucose perturbations and cardiovascular risk: challenges and opportunities
Rydén L, Mellbin L
Diabetes & vascular disease research 2012;9(3):170-6

Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?
Rydén L, Mellbin L
Current vascular pharmacology 2012;10(6):690-2

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
Origin Trial Investigators, Bosch J, Gerstein Hc, Dagenais Gr, Díaz R, Dyal L, et al
The New England journal of medicine 2012;367(4):309-18

[Pay for disease or invest in health?]
Rydén L, Andersen K, Gyberg V, Mellbin L
Lakartidningen 2012;109(36):1535-9

Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study
Digami 2 Investigators, Mellbin Lg, Malmberg K, Norhammar A, Wedel H, Ryden L
DIABETOLOGIA 2011;54(6):1308-17

Copeptin, IGFBP-1, and Cardiovascular Prognosis in Patients With Type 2 Diabetes and Acute Myocardial Infarction A report from the DIGAMI 2 trial
Mellbin Lg, Ryden L, Brismar K, Morgenthaler Ng, Ohrvik J, Catrina Sb
DIABETES CARE 2010;33(7):1604-6

Diabetes, prediabetes and cardiovascular risk
Mellbin Lg, Anselmino M, Ryden L
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2010;:S9-14

Glucose Monitoring by Means of an Intravenous Microdialysis Catheter Technique
Hage C, Mellbin L, Ryden L, Wernerman J
DIABETES TECHNOLOGY & THERAPEUTICS 2010;12(4):291-5

Insulin in patients with acute myocardial infarction and diabetes, friend or foe? A report from the Digami 2 study
Mellbin L, Malmberg K, Norhammar A, Wedel H, Ryden L
EUROPEAN HEART JOURNAL 2010;:343-344

Insulin in patients with acute myocardial infarction and diabetes - friend or foe? A report from the DIGAMI 2 study
Mellbin Lg, Malmberg K, Norhammar A, Wedel H, Ryden L
DIABETOLOGIA 2010;:S22-S22

Mannose-binding lectin genotype and phenotype and their impact on cardiovascular prognosis in patients with type 2 diabetes and myocardial infarction; a report from the DIGAMI 2 trial
Mellbin L, Ryden L, Hamsten A, Malmberg K, Steffensen R, Ohrvik J, et al
EUROPEAN HEART JOURNAL 2010;:345-345

Mannose-Binding Lectin Genotype and Phenotype in Patients With Type 2 Diabetes and Myocardial Infarction
Mellbin Lg, Hamsten A, Malmberg K, Steffensen R, Ryden L, Ohrvik J, et al
DIABETES CARE 2010;33(11):2451-6

NT-proBNP is a potent prognostic marker in patients with type 2 diabetes hospitalized for acute coronary syndrome - a DIGAMI 2 sub study
Gustafsson I, Mellbin L, Dickstein K, Malmberg K, Ryden L, Torp-pedersen C, et al
EUROPEAN HEART JOURNAL 2010;:514-515

Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting
Anselmino M, Malmberg K, Mellbin L, Ryden L
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS 2010;11(1):87-94

Copeptin predicts and explains the association between IGFBP-1 and cardiovascular events in patients with type 2 diabetes and myocardial infarction
Catrina Sb, Mellbin Lg, Morgenthaler Ng, Botusan Ir, Ryden L, Ohrvik J, et al
DIABETOLOGIA 2009;:S522-S522

Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus?
Ryden L, Malmberg K, Mellbin L
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM 2009;5(1):8-9

Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial
Digami 2 Investigators, Mellbin Lg, Malmberg K, Waldenstrom A, Wedel H, Ryden L
HEART 2009;95(9):721-7

Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?
Mellbin Lg, Ryden L, Malmberg K, Norhammar A, Wedel H
EUROPEAN HEART JOURNAL 2008;29(16):2058-2059

Cardiovascular prevention in patients with diabetes and prediabetes
Anselmino M, Gohlke H, Mellbin L, Ryden L
HERZ 2008;33(3):170-7

Early detection and integrated management of dysglycemia in cardiovascular disease: A key factor for decreasing the likelihood of future events
Anselmino M, Mellbin L, Wallander M, Ryden L
REVIEWS IN CARDIOVASCULAR MEDICINE 2008;9(1):29-38

Glucose, insulin, and coronary heart disease: reply
Mellbin Lg, Malmberg K, Norhammar A, Ryden L
EUROPEAN HEART JOURNAL 2008;29(8):1076-1077

Implications of abnormal glucose metabolism in patients with coronary artery disease
Anselmino M, Wallander M, Norhammar A, Mellbin L, Ryden L
DIABETES & VASCULAR DISEASE RESEARCH 2008;5(4):285-90

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial
Digami 2 Investigators, Mellbin Lg, Malmberg K, Norhammar A, Wedel H, Ryden L
EUROPEAN HEART JOURNAL 2008;29(2):166-76

Show all publications